THE PAIN BLOCK™ SYSTEM
Innovativa läkemedelför lokal smärtblockering på huden
Vetenskapsbaserad topikal teknologi utvecklad för lokal och riktad behandling direkt där smärtan och irritationen uppstår.
A Swedish innovation with global potential
Auxesis Pharma is approaching commercialization. With patented technology, a growing product portfolio and upcoming local manufacturing in Sweden, we are building a long-term path to the global market.
For investors, this is a unique opportunity to join the journey as Swedish drug development meets international demand. We combine scientifically validated effect with a scalable business model, positioning Auxesis Pharma as a future player in innovative medicines.
Innovation and product development
Swedish Pharmaceutical Innovation with a Focus on Skin
We have successfully stabilized acetylsalicylic acid in liquid form – a formulation that has long presented a significant pharmaceutical challenge. Through our proprietary technology, we are creating new opportunities for localized treatment directly on the skin, where the active ingredient is designed to act without unnecessary systemic exposure.
Behind our pharmaceutical developments is a Swedish team with expertise in research, drug development, and clinical medicine. Together, we develop innovative treatments with a focus on science, safety, and patient benefit – from early research to clinical trials and future commercialization.
Topical Platform Technology
Skin pain should be treated where it occurs
Auxesis Pharma develops topical treatments designed to act directly at the source of pain and irritation in the skin.
Our technology is based on a stabilized liquid form of acetylsalicylic acid, developed for precise local application without unnecessary systemic exposure.
The platform forms the foundation for ASA.P® and several future products within human medicine, aesthetic dermatology, cosmeceuticals and veterinary medicine.
The first product on the platform
ASA.P® – local treatment of skin pain
ASA.P® is the first product being developed on Auxesis Pharma’s topical technology platform. It is designed to treat pain and irritation directly in the affected area of the skin.
The stabilized liquid form of ASA penetrates locally, reaches and blocks COX signals at the source of pain and remains where it is needed.
- Local application directly to the skin
- Non-systemic action
- Targeted treatment at the source of pain
- Developed for rapid effect
Different types of skin pain
ASA.P® is being developed to block pain signals locally in the skin and treat pain and irritation where they occur.
0106
Lokal hudsmärta
Wasp stings
Wasp stings can cause intense local pain, a burning sensation, swelling and redness.
Scientific publications on pain, ASA and COX-2
Research
COX-2 inhibitors — Nature Scientific Reports
Research on COX-2 inhibitors and their mechanisms.
Nerve cells
Nerve cells in human skin perform advanced computations
Topical NSAIDs — Mayo Clinic
Information on topical anti-inflammatory medicines.
Karolinska Institutet — Inflammation Research
Swedish research on pain and inflammatory mechanisms.
Topical pain products on the market
Veterinary medicine & animal health
Latest from Auxesis Pharma
An exciting autumn for Auxesis Pharma
Read more →
Dermatology
Read more →
Auxesis Pharma strengthens its medical expertise
Read more →